Literature DB >> 25761376

Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study.

Laura E Jonkman1, Alexandra Lopez Soriano, Sandra Amor, Frederik Barkhof, Paul van der Valk, Hugo Vrenken, Jeroen J G Geurts.   

Abstract

In multiple sclerosis (MS), a histopathological distinction is made between different stages of white matter (WM) lesions. These lesions are characterized as preactive, active, chronic active or chronic inactive, depending on the degree of microglia activation and degree of demyelination. The different lesions are not distinguishable on conventional magnetic resonance imaging (MRI) scans at standard clinical field strengths, but might be distinguished using more advanced, quantitative MRI methods, such as T1 relaxation time (T1-RT) mapping. To investigate this, postmortem brain material from 20 MS patients was investigated, using both T1-RT MRI at 1.5 T and histopathology. The brain material contained a total of 9 preactive, 18 active, 30 chronic active and 14 chronic inactive lesions, as well as 38 areas of normal appearing WM (NAWM). Our results show that, at 1.5 T, T1-RT qMRI can only distinguish between categories NAWM/preactive, active and chronic WM lesions. Advanced imaging at standard field strengths, such as conventional imaging measures, is therefore insufficient to differentiate the WM lesions in MS, and higher field strengths may be required to achieve better pathological differentiation of these lesions.

Entities:  

Mesh:

Year:  2015        PMID: 25761376      PMCID: PMC4412507          DOI: 10.1007/s00415-015-7689-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


Introduction

Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system (CNS). Pathologically, a distinction can be made between different stages of white matter (WM) lesions that may be characterized as preactive, active, chronic active or chronic inactive, depending on their degree of microglia activation, adaptive immune response and demyelination [1]. Preactive lesions still have normal myelin density and morphology, but already show clusters of activated microglia. Active lesions show sharply bordered demyelination with myelin-laden macrophages. In chronic active lesions, macrophages have migrated to the rim of the lesion, leaving the center fully demyelinated and hypocellular. In chronic inactive lesions, there is complete demyelination; microglia and macrophages are no longer present. Conventional magnetic resonance imaging (MRI) techniques, such as T2-weighted MRI, are highly sensitive to MS WM lesions [2, 3] but do not provide information on the aforementioned pathological heterogeneity. However, for clinical purposes, it would be extremely useful if this pathological distinction could be made in vivo. This way, an inflammatory profile of MS patients could be more accurately described; the clinical impact of these different lesion stages, as well as their development over time, their occurrence in different patient and disease stages and their responsiveness to therapy could be monitored. Currently, the technique of choice for visualizing active inflammatory WM lesions in vivo requires the administration of intravenous contrast agents. Quantitative MRI (qMRI) techniques, such as quantitative T1 relaxation time (RT) mapping, have shown to be both sensitive and more pathologically specific [4-7]. T1-RT correlates with myelin content and axonal count, which are both decreased in lesions compared to NAWM, and axonal count differs between different lesion stages [8, 9]. T1-RT mapping should therefore have the potential to detect inflammatory lesions at earlier stages and with more subtle pathology, which are now only evident postmortem. Use of such advanced MRI techniques could then improve clinical correlations of MRI-detectable abnormalities in vivo, as these correlations are generally low when using conventional techniques [10]. Therefore, the current study used advanced postmortem MRI and histopathology correlation to investigate whether T1-RT mapping can be used to distinguish the different stages of WM demyelination in MS.

Methods

Patients and autopsy

Coronal brain sections of 20 patients with MS (11 females, 9 males, mean age at autopsy 63.6 ± 11.5 years, mean disease duration 26.2 ± 15.3 years) were obtained after rapid autopsy (mean postmortem delay 8 h 21 min). Table 1 provides the demographic and neuropathological details of the donors. Autopsy procedure and tissue sampling followed the MS Center Amsterdam autopsy protocol which has been described previously [11]. Briefly, for each patient, five 10-mm-thick coronal hemispheric brain sections were cut and subjected to MR imaging. WM abnormalities visible on T2-weighted imaging were sampled.
Table 1

Demographic and neuropathology data of patients

PatientSexAgeDD (years)PMD (h:min)Scannera MS typeCause of death
1F44810:151PPMSHeart failure
2M63247:051SPMSCardiac arrest
3F69537:301SPMSHeart failure
4F70406:551SPMSUrine tract infection
5F572120:001SPMSDecubitus
6F76199:451SPMSUnknown
7F81644:001SPMSUnknown
8M50155:252PPMSPulmonary carcinoma
9F66226:002SPMSUnknown
10M49248:002SPMSPneumonia
11F772410:002SPMSEuthanasia
12M72237:552SPMSPneumonia
13M56145:002SPMSCachexia
14F6078:502PPMSEuthanasia
15M54128:152PPMSEuthanasia
16M755010:102SPMSPneumonia
17F50177:352SPMSEuthanasia
18M673711:002SPMSHeart failure
19M54297:002SPMSEuthanasia
20F81216:302PPMSHeart failure
Mean ± SD63.6 ± 11.526.2 ± 15.38:21

PMD postmortem delay (h:min), DD disease duration in years since diagnosis

aScanner; 1, Avanto; 2, Sonata

Demographic and neuropathology data of patients PMD postmortem delay (h:min), DD disease duration in years since diagnosis aScanner; 1, Avanto; 2, Sonata

MRI protocol and qMRI maps

The postmortem brain slices were scanned according to our autopsy protocol [11, 12], using a whole body 1.5T magnetic resonance system (Sonata and Avanto, Siemens Medical Systems, Erlangen, Germany) with a standard circularly polarized head coil (Sonata) or a 12-channel phased-array head coil (Avanto). Conventional Pd/T2-weighted images were acquired (TR/TE1/TE2: 2500/85/24 ms, in-plane resolution 0.5 mm × 0.5 mm, slice thickness 4 mm), centered in the middle of the slice and parallel to the coronal surface. For T1 mapping, six sets of images were acquired using a 3D gradient echo sequence (3D-FLASH; TR/TE: 20/4 ms; in-plane resolution 1 mm × 1 mm, slice thickness 4 mm), covering the same volume as the Pd/T2-weighted images. Flip angles were 2°, 5°, 10°, 15°, 20° and 25°, respectively. For B1-mapping, five sets of images were acquired (TR/TE: 20/4 ms, in-plane resolution 2 mm × 2 mm, slice thickness 4 mm). Flip angles were 140°, 160°, 180°, 200° and 220°, respectively.

Image analysis

Pixel-by-pixel T1 calculations were performed with B1 correction as described by Venkatesan et al. [13]. Briefly, B1 maps were generated from the image volumes with nominal flip angles between 140° and 220° by determining the ratio between the true and nominal flip angle from the signal zero crossing that occurs at a true flip angle of 180°. Subsequently, T1 was determined for each pixel through a nonlinear least squares fit by using the image and the calculated B1 map [13].

Histopathology and immunohistochemistry

After MRI, the tissue blocks were fixed in 10 % formalin, routinely processed and embedded in paraffin. Subsequently, 5 µm-thick sections were cut, mounted onto glass slides (Superfrost, VWR international, Leuven, Belgium) and dried overnight at 37 °C. Sections were deparaffinized in a series of xylene, 100 % ethanol, 96 % ethanol, 70 % ethanol and water. Endogenous peroxidase activity was blocked by incubating the sections in methanol with 0.3 % H2O2 for 30 min. After this, the sections were rinsed with 0.01 mol/L phosphate-buffered saline (PBS, pH 7.4). Staining and immunohistochemistry were performed on adjacent sections with antibodies against the following targets: microglia/macrophages (anti-HLA-DR, clone LN3) and proteolipid protein (PLP; Serotec, Oxford, UK). Bound primary antibodies were detected using EnVision method (DAKOCytomation, Glostrup, Denmark) and 3,3′diaminobenzidine-tetrahydrochloride dihydrate (DAB) was used as a chromogen. Sections were counterstained with hematoxylin and mounted (Depex, BDH; Poole, UK).

Scoring, classification and matching

WM lesions were scored by an experienced pathological examiner (PvdV) and classified according to the van der Valk and De Groot criteria [1] into preactive, active, chronic active and chronic inactive lesions. Preactive lesions show myelin and clusters of activated microglia. Active lesions show sharply bordered demyelination with macrophages. Chronic active lesions show macrophages at the rim of the lesion, and in chronic inactive lesions microglia and macrophages are no longer present. In total, 71 WM lesions were selected: 9 preactive, 18 active, 30 chronic active and 14 chronic inactive lesions. Furthermore, 38 areas of normal appearing WM (NAWM) were selected after histopathological inspection. Sections containing WM lesions were matched to corresponding postmortem T2-weighted MR images as described previously [12]; see Fig. 1 for an example. Lesions were outlined (ROIs) on the T2 images using MIPAV software (Medical Image Processing, Analysis and Visualization, National Institutes of Health; mipav.cit.nih.gov). Subsequently, ROIs were copied onto the T1 qMRI maps and T1-RT values were obtained. ROIs were also placed in the NAWN, so as to act as a control measurement. An average T1-RT value was obtained over all voxels within a ROI (lesion or NAWM). Then each lesional/NAWM T1-RT value was assigned to their corresponding histopathological group (preactive, active, chronic active, chronic inactive or NAWM) and statistical analysis was performed. A flowchart of the autopsy, histological, matching and analyzing procedure can be found in Fig. 2.
Fig. 1

Matching of T2-w image and T1 map with histology. T2 image (a, e, i, m) and T1 map (b, f, j, n) with a red box indicating lesion location. A preactive lesion (a–d), an active lesion (e–h), a chronic active lesion (i–l) and a chronic inactive lesion (m–p). Lesions are visualized by histological sections of PLP (c, g, k, o) and LN3 (d, h, l, p) stainings. Note that outside the brain slice, due to the virtual absence of protons, T1-RT fits give unreliable results. However, to present un unbiased view of our analysis, we present the full data in the T1-RT images in this figure. The range for T1-RT maps is set between 500 ms (black) and 1,500 ms (white)

Fig. 2

Flowchart of postmortem MRI with histology, matching and analysis

Matching of T2-w image and T1 map with histology. T2 image (a, e, i, m) and T1 map (b, f, j, n) with a red box indicating lesion location. A preactive lesion (a–d), an active lesion (e–h), a chronic active lesion (i–l) and a chronic inactive lesion (m–p). Lesions are visualized by histological sections of PLP (c, g, k, o) and LN3 (d, h, l, p) stainings. Note that outside the brain slice, due to the virtual absence of protons, T1-RT fits give unreliable results. However, to present un unbiased view of our analysis, we present the full data in the T1-RT images in this figure. The range for T1-RT maps is set between 500 ms (black) and 1,500 ms (white) Flowchart of postmortem MRI with histology, matching and analysis

Statistical analysis

Descriptive and statistical analysis was performed using SPSS 20.0 for windows (SPSS, Inc., Chicago, IL). For the analysis between lesion types, we used the general estimated equation (GEE) for related data (71 lesions from 20 patients; some lesions from the same patient and therefore not independent). Scanner (Sonata or Avanto) and lesion area (mm2) were added as covariates. Holm–Bonferroni correction was used for multiple testing; significance level was set at p < 0.05.

Results

T1-RT increased consistently when moving from NAWM through preactive and active lesions to chronic lesions. Table 2 provides an overview of the mean (±SD) T1-RT values of the different lesion types. Statistical analysis of T1-RT revealed that NAWM differed significantly from active, chronic active and chronic inactive lesion types (all p < 0.001). Preactive lesions also differed significantly from active, chronic active and chronic inactive lesion types (all p < 0.001). However, NAWM and preactive lesions did not differ significantly from each other (p = 0.742). Furthermore, active lesions differed significantly from chronic inactive lesions (p < 0.05), but not from chronic active lesions (p = 0.286). Chronic active and chronic inactive lesions did not differ significantly from each other (p = 0.316). When lesion types were grouped into three distinct groups, i.e., NAWM/preactive (mean T1-RT = 798.32 ± 67.72 ms), active (mean T1-RT = 1140.89 ± 204.82 ms) and chronic (mean T1-RT = 1271.36 ± 231.19 ms, including chronic active and chronic inactive lesions), all three groups differed significantly from each other. In other words, NAWM/preactive lesions differed significantly from active (p < 0.05) and chronic lesions (p < 0.001), and active lesions differed significantly from chronic lesions (p < 0.05).
Table 2

Mean, standard deviation and minimum and maximum of T1-RT (in ms) for lesion types

Lesion type/tissueMeanStandard deviationMinimumMaximum
NAWMc 785.1578.69704.20981.22
Preactivec 846.1566.11744.50939.00
Activea,b 1140.89204.82839.501432.45
Chronic activea,b 1225.58197.771003.031561.04
Chronic inactivea,b,d 1320.32370.05942.972171.69

aSignificant difference (p < 0.001) with normal appearing white matter (NAWM)

bSignificant difference (p < 0.001) with preactive lesions

cSignificant difference (p < 0.001) with active lesions

dSignificant difference (p < 0.05) with active lesions

Mean, standard deviation and minimum and maximum of T1-RT (in ms) for lesion types aSignificant difference (p < 0.001) with normal appearing white matter (NAWM) bSignificant difference (p < 0.001) with preactive lesions cSignificant difference (p < 0.001) with active lesions dSignificant difference (p < 0.05) with active lesions

Discussion

In the current study, we set out to investigate whether the different stages of WM demyelination that are defined in MS histopathology can be differentiated by quantitative T1-RT mapping. Upon analysis of the data, histopathologically defined WM lesion types could be distinguished from NAWM, and a distinction could also be made between the overarching categories NAWM/preactive, active and chronic lesions (including chronic active and chronic inactive lesions). However, further subclassification into pathological lesion types based on T1-RT measures was not possible. This means that, at a standard clinical field strength of 1.5T, there is additional value in distinguishing active from chronic lesions, but determining which exact lesion types are predominant in which patients or how specific lesional stages correlate with clinical disability is still limited and requires more research, possibly at higher field strength with better signal-to-noise ratio and spatial resolution. T1-RT measurement would still be an interesting MRI candidate at higher field strength, as this technique is highly sensitive to pathology and may detect tissue abnormalities where other advanced MRI techniques cannot [4]. This remains important when attempting to visualize subtle tissue pathology such as microglial clustering or incipient demyelination. However, future studies would probably benefit from combining T1-RT with other advanced MRI measures, such as MTR or DTI, as a combination of qMRI metrics with different pathological substrates may increase pathological specificity and hence improve MRI characterization of lesional heterogeneity in MS. A limitation of this study is that although from in vivo measurements it is known that the accuracy and reproducibility of the T1-RT mapping method used are acceptable given the field strength [4, 13], we cannot fully exclude that there may be T1-RT errors related specifically to its application in fresh brain slices. Due to the rapid autopsy setting, imaging time had to be minimized to preserve tissue. Therefore, there was no time to perform a direct quantification of any potential errors related specifically to the application in fresh brain slices by, e.g., comparing to a trusted other technique such as inversion recovery spin echo imaging with an array of inversion times, because of the long acquisition times for such techniques. Furthermore, our sample size was limited when looking at the numbers of lesions within some of the lesion categories. As a result, the power to detect differences between, e.g., preactive and other types of lesions or NAWM was a priori low. However, if lesion differentiation can be improved by future (q)MRI efforts, a translation to the in vivo setting would be highly interesting. Initially, sensitivity and specificity of classifying lesions by qMRI, or T1-RT in particular, would have to be determined. Subsequently, an in vivo study with parameters similar to those used in this postmortem study is recommended, to see how T1-RT values change between the postmortem and in vivo setting and how this affects classification. Lesional changes may then be studied in vivo and in direct relation to clinical disability, and questions regarding homo- or heterogeneity of lesional pathology within and between patients [14, 15] as well as specific responses of lesions to treatment could and should then be addressed.
  15 in total

1.  T2 lesions and rate of progression of disability in multiple sclerosis.

Authors:  J P Mostert; M W Koch; C Steen; D J Heersema; J C De Groot; J De Keyser
Journal:  Eur J Neurol       Date:  2010-12       Impact factor: 6.089

2.  Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types.

Authors:  H Vrenken; A Seewann; D L Knol; C H Polman; F Barkhof; J J G Geurts
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-22       Impact factor: 3.825

3.  Accurate determination of spin-density and T1 in the presence of RF-field inhomogeneities and flip-angle miscalibration.

Authors:  R Venkatesan; W Lin; E M Haacke
Journal:  Magn Reson Med       Date:  1998-10       Impact factor: 4.668

4.  Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis.

Authors:  H Vrenken; J J G Geurts; D L Knol; C H Polman; J A Castelijns; P J W Pouwels; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2006-10       Impact factor: 3.825

Review 5.  Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders.

Authors:  C Lucchinetti
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

Review 6.  T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis.

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Venkata S R Dandamudi; Courtney E Batt; Zachary D Guss; Ali Al-Sabbagh; Rohit Bakshi
Journal:  J Neuroimaging       Date:  2007-04       Impact factor: 2.486

Review 7.  Translating pathology in multiple sclerosis: the combination of postmortem imaging, histopathology and clinical findings.

Authors:  A Seewann; E-J Kooi; S D Roosendaal; F Barkhof; P van der Valk; J J G Geurts
Journal:  Acta Neurol Scand       Date:  2009-02-26       Impact factor: 3.209

Review 8.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

9.  Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation.

Authors:  Klaus Schmierer; Claudia A M Wheeler-Kingshott; Daniel J Tozer; Phil A Boulby; Harold G Parkes; Tarek A Yousry; Francesco Scaravilli; Gareth J Barker; Paul S Tofts; David H Miller
Journal:  Magn Reson Med       Date:  2008-02       Impact factor: 4.668

10.  Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain.

Authors:  Klaus Schmierer; Francesco Scaravilli; Daniel R Altmann; Gareth J Barker; David H Miller
Journal:  Ann Neurol       Date:  2004-09       Impact factor: 10.422

View more
  12 in total

1.  Post-mortem 1.5T MR quantification of regular anatomical brain structures.

Authors:  Wolf-Dieter Zech; Anna-Lena Hottinger; Nicole Schwendener; Frederick Schuster; Anders Persson; Marcel J Warntjes; Christian Jackowski
Journal:  Int J Legal Med       Date:  2016-02-12       Impact factor: 2.686

2.  Longitudinal multiple sclerosis lesion segmentation: Resource and challenge.

Authors:  Aaron Carass; Snehashis Roy; Amod Jog; Jennifer L Cuzzocreo; Elizabeth Magrath; Adrian Gherman; Julia Button; James Nguyen; Ferran Prados; Carole H Sudre; Manuel Jorge Cardoso; Niamh Cawley; Olga Ciccarelli; Claudia A M Wheeler-Kingshott; Sébastien Ourselin; Laurence Catanese; Hrishikesh Deshpande; Pierre Maurel; Olivier Commowick; Christian Barillot; Xavier Tomas-Fernandez; Simon K Warfield; Suthirth Vaidya; Abhijith Chunduru; Ramanathan Muthuganapathy; Ganapathy Krishnamurthi; Andrew Jesson; Tal Arbel; Oskar Maier; Heinz Handels; Leonardo O Iheme; Devrim Unay; Saurabh Jain; Diana M Sima; Dirk Smeets; Mohsen Ghafoorian; Bram Platel; Ariel Birenbaum; Hayit Greenspan; Pierre-Louis Bazin; Peter A Calabresi; Ciprian M Crainiceanu; Lotta M Ellingsen; Daniel S Reich; Jerry L Prince; Dzung L Pham
Journal:  Neuroimage       Date:  2017-01-11       Impact factor: 6.556

3.  Silent cerebral infarct definitions and full-scale IQ loss in children with sickle cell anemia.

Authors:  Natasha A Choudhury; Michael R DeBaun; Mark Rodeghier; Allison A King; John J Strouse; Robert C McKinstry
Journal:  Neurology       Date:  2017-12-20       Impact factor: 9.910

4.  T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.

Authors:  C Thaler; T D Faizy; J Sedlacik; B Holst; K Stürner; C Heesen; J-P Stellmann; J Fiehler; S Siemonsen
Journal:  AJNR Am J Neuroradiol       Date:  2016-11-10       Impact factor: 3.825

5.  Periventricular gradient of T1 tissue alterations in multiple sclerosis.

Authors:  Manuela Vaneckova; Gian Franco Piredda; Michaela Andelova; Jan Krasensky; Tomas Uher; Barbora Srpova; Eva Kubala Havrdova; Karolina Vodehnalova; Dana Horakova; Tom Hilbert; Bénédicte Maréchal; Mário João Fartaria; Veronica Ravano; Tobias Kober
Journal:  Neuroimage Clin       Date:  2022-04-16       Impact factor: 4.891

6.  The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.

Authors:  Christian Thaler; Tobias D Faizy; Jan Sedlacik; Maxim Bester; Jan-Patrick Stellmann; Christoph Heesen; Jens Fiehler; Susanne Siemonsen
Journal:  J Neurol       Date:  2017-11-20       Impact factor: 4.849

7.  Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.

Authors:  Cristina Granziera; Jens Wuerfel; Frederik Barkhof; Massimiliano Calabrese; Nicola De Stefano; Christian Enzinger; Nikos Evangelou; Massimo Filippi; Jeroen J G Geurts; Daniel S Reich; Maria A Rocca; Stefan Ropele; Àlex Rovira; Pascal Sati; Ahmed T Toosy; Hugo Vrenken; Claudia A M Gandini Wheeler-Kingshott; Ludwig Kappos
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

8.  Loss of corticospinal tract integrity in early MS disease stages.

Authors:  Marc Pawlitzki; Jens Neumann; Jörn Kaufmann; Jan Heidel; Erhard Stadler; Catherine Sweeney-Reed; Michael Sailer; Stefanie Schreiber
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-09-25

9.  T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.

Authors:  Christian Thaler; Tobias Faizy; Jan Sedlacik; Brigitte Holst; Jan-Patrick Stellmann; Kim Lea Young; Christoph Heesen; Jens Fiehler; Susanne Siemonsen
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

10.  Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis.

Authors:  Marco Puthenparampil; Lisa Federle; Davide Poggiali; Silvia Miante; Alessio Signori; Elisabetta Pilotto; Francesca Rinaldi; Paola Perini; Maria Pia Sormani; Edoardo Midena; Paolo Gallo
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.